**Core Concept**
The diagnosis of melanoma in a patient with a history of melanoma requires identification of tumor cells using specific immunohistochemical markers. This case presents a unique challenge due to the patient's history of breast cancer and the presence of a hemorrhagic nodule in the brain.

**Why the Correct Answer is Right**
The correct answer is S100 protein, a calcium-binding protein that is commonly expressed in melanocytes. S100 protein is a sensitive and specific marker for melanoma, and it is often used in conjunction with other markers such as HMB-45 and Melan-A to confirm the diagnosis. The presence of S100 protein in the tumor cells would support the diagnosis of melanoma, particularly in the context of a patient with a history of melanoma.

**Why Each Wrong Option is Incorrect**
**Option A:** BRAF V600E mutation is a common genetic alteration in melanoma, but it is not a specific marker for melanoma diagnosis. While BRAF V600E mutation can be used to guide treatment, it is not as helpful in making the diagnosis definitive.

**Option B:** Cytokeratin is a marker for epithelial cells, and it is often used to identify carcinomas. However, melanoma is a neuroectodermal tumor, and cytokeratin is not specific for this diagnosis.

**Option C:** Vimentin is a marker for mesenchymal cells, and it is often used to identify sarcomas. While vimentin can be expressed in some melanomas, it is not specific for this diagnosis, and it would not be the most helpful marker in this case.

**Clinical Pearl / High-Yield Fact**
Melanoma can metastasize to the brain, and it is essential to consider this diagnosis in patients with a history of melanoma who present with seizures or other neurological symptoms.

**Correct Answer:** S100 protein.